OTPP-2 funding will prioritize services to be delivered to and within the following IDPH regions: West Chicago, Peoria, Champaign, and Metro East. Services to other regions and communities will be considered.
The goal of OTPP–2 is to increase access to all forms of medication assisted recovery (MAR) throughout Illinois for people with opioid use disorder (OUD) or polysubstance use disorder (including opioids), focusing on disparately impacted populations. MAR is the use of Food and Drug Administration (FDA) approved medications to treat substance use disorder. Currently, medications approved to treat opioid use disorder include methadone, buprenorphine, and naltrexone. MAR is the equivalent of Medications for Opioid Use Disorder, or MOUD. This will be achieved through the following objectives:
- Forge partnerships between opioid treatment programs (OTPs) and Federally Qualified Health Centers (FQHCs), hospitals, clinics, or public departments of health.
- Establish new OTPs, new medication units (satellites) of existing OTPs, or new partnerships allowing greater access to all three forms of Food and Drug Administration (FDA)-approved medications to treat substance use disorders (SUDs) in regions of the state not currently served adequately by existing OTPs and medication units (“MAR deserts”).
- Create collaborative care models supported by the above partnerships to ensure patients have access to comprehensive substance use disorder services, including physical (medical), behavioral health, and recovery support services (42 CFR § 8.2).
Up to four (4) organizations will be awarded funds to fulfill the requirements of the subaward.
Services provided under this NOFO shall reflect the Illinois Department of Human Services’ (IDHS) commitment to advancing equity and racial and social justice by enabling all to thrive, regardless of race, ZIP Code, and disability.
Questions about the OTPP-2 NOFO are due by Friday, April 24, 2026, 5:00 p.m. CT.
Applications are due Friday, May 8, 2026, 5:00 p.m. CT.
OTPP-2 NOFO
OTPP-2 funding will prioritize services to be delivered to and within the following IDPH regions: West Chicago, Peoria, Champaign, and Metro East. Services to other regions and communities will be considered.
The goal of OTPP–2 is to increase access to all forms of medication assisted recovery (MAR) throughout Illinois for people with opioid use disorder (OUD) or polysubstance use disorder (including opioids), focusing on disparately impacted populations. MAR is the use of Food and Drug Administration (FDA) approved medications to treat substance use disorder. Currently, medications approved to treat opioid use disorder include methadone, buprenorphine, and naltrexone. MAR is the equivalent of Medications for Opioid Use Disorder, or MOUD. This will be achieved through the following objectives:
- Forge partnerships between opioid treatment programs (OTPs) and Federally Qualified Health Centers (FQHCs), hospitals, clinics, or public departments of health.
- Establish new OTPs, new medication units (satellites) of existing OTPs, or new partnerships allowing greater access to all three forms of Food and Drug Administration (FDA)-approved medications to treat substance use disorders (SUDs) in regions of the state not currently served adequately by existing OTPs and medication units (“MAR deserts”).
- Create collaborative care models supported by the above partnerships to ensure patients have access to comprehensive substance use disorder services, including physical (medical), behavioral health, and recovery support services (42 CFR § 8.2).
Up to four (4) organizations will be awarded funds to fulfill the requirements of the subaward.
Services provided under this NOFO shall reflect the Illinois Department of Human Services’ (IDHS) commitment to advancing equity and racial and social justice by enabling all to thrive, regardless of race, ZIP Code, and disability.
Questions about the OTPP-2 NOFO are due by Friday, April 24, 2026, 5:00 p.m. CT.
Applications are due Friday, May 8, 2026, 5:00 p.m. CT.